Welcome to our dedicated page for Bioharvest news (Ticker: CNVCF), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bioharvest's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bioharvest's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioHarvest Sciences Inc. (CSE: BHSC) announced strong Q3 2021 results, reporting VINIA® sales of USD 688K, a 44% increase from Q2 and a remarkable 1,198% growth compared to Q3 2020. In Israel, sales orders reached USD 452K, while USD 236K came from the U.S. pilot program, marking 251% growth over Q2. The company is preparing to launch a new manufacturing facility in Israel to meet increasing demand. Financing activities raised USD 3.48M through private placements and USD 4.41M from warrants, supporting its growth initiatives.